V503 + GARDASIL
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Human Papillomavirus
Conditions
Human Papillomavirus
Trial Timeline
Feb 23, 2011 → Dec 20, 2011
NCT ID
NCT01304498About V503 + GARDASIL
V503 + GARDASIL is a phase 3 stage product being developed by Merck for Human Papillomavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT01304498. Target conditions include Human Papillomavirus.
What happened to similar drugs?
14 of 20 similar drugs in Human Papillomavirus were approved
Approved (14) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03998254 | Phase 3 | Active |
| NCT02653118 | Pre-clinical | Active |
| NCT02114385 | Phase 3 | Completed |
| NCT01304498 | Phase 3 | Completed |
Competing Products
20 competing products in Human Papillomavirus